National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Simeprevir (Olysio®) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients as part of a triple therapy regimen (co-administered with PegInterferon + Ribavirin) to treat hepatitis C virus (HCV) Genotypes 1 and 4 who are treatment naïve or have previously been treated.

Rapid Review

Commenced Completed Outcome
27/05/2014 11/07/2014 Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin.